Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559246 | 0.90 | TDP1 (0.63) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL30784403 | 0.85 | MAPT (0.70) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL4403599 | 0.85 | MAPT (0.58) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL29788065 | 0.84 | TDP1 (0.74) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL2039778 | 0.84 | TDP1 (0.74) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL2636213 | 0.84 | TDP1 (0.74) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL2039548 | 0.84 | MAPT (0.80) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL29788183 | 0.84 | MAPT (0.80) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL31250016 | 0.82 | MAPT (0.54) | TDP1KMT2AGAAPOLBMAPT | |
| SCHEMBL3435055 | 0.82 | MAPT (0.74) | TDP1KMT2APOLBMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1523475-B1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-12-23 | — | — | EP | disclosed |
| CN-1304371-C | Heterocyclically substituted benzoylureas, medicaments thereof and use for producing medicaments | AVENTIS PHARMA GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-7138414-B2 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-21 | — | — | US | disclosed |
| CN-1668593-A | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1523475-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | US | disclosed |
| WO-2004007455-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SLC5A2, CYP1A2, HBB | TDP1 3078/4885KMT2A 2633/4885GAA 712/4885 |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SLC5A2, CYP1B1, CYP2C19 | TDP1 2188/4885KMT2A 3209/4885GAA 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.